Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease
Science · 13.01.2023 · 379 (6628) · 179-185
DOI: 10.1126/science.ade1105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 13.01.2023. Verfasst von Simon Lebek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Gene Editing, Heart Diseases, Calcium-Calmodulin-Dependent Protein Kinase Type 2. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NICHD NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
CRISPR-Cas9 gene editing is emerging as a prospective therapy for genomic mutations. However, current editing approaches are directed primarily toward relatively small cohorts of patients with specific mutations. Here, we describe a cardioprotective strategy potentially applicable to a broad range of patients with heart disease. We used base editing to ablate the oxidative activation sites of CaMKIIδ, a primary driver of cardiac disease. We show in cardiomyocytes derived from human induced pluripotent stem cells that editing the CaMKIIδ gene to eliminate oxidation-sensitive methionine residues confers protection from ischemia/reperfusion (IR) injury. Moreover, CaMKIIδ editing in mice at the time of IR enables the heart to recover function from otherwise severe damage. CaMKIIδ gene editing may thus represent a permanent and advanced strategy for heart disease therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
- Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
ORCID-Profile: Simon Lebek, Francesco Chemello, Xurde M Caravia, Wei Tan, Hui Li, Lin Xu, Ning Liu, Rhonda Bassel-Duby, Eric N Olson
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Lebek, S., Chemello, F., Caravia, X. M., Tan, W., Li, H., Chen, K., Xu, L., Liu, N., Bassel-Duby, R., & Olson, E. N. (2023). Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science, 379(6628), 179-185. https://doi.org/10.1126/science.ade1105
Vancouver
Lebek S, Chemello F, Caravia XM, Tan W, Li H, Chen K, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 2023;379(6628):179-185. doi:10.1126/science.ade1105
BibTeX
@article{Lebek2023,
author = {Lebek, Simon and Chemello, Francesco and Caravia, Xurde M and Tan, Wei and Li, Hui and Chen, Kenian and Xu, Lin and Liu, Ning and Bassel-Duby, Rhonda and Olson, Eric N},
title = {Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease},
journal = {Science},
year = {2023},
volume = {379},
number = {6628},
pages = {179--185},
doi = {10.1126/science.ade1105}
}
EUVIMED